原发性肝癌介入联合靶向及免疫治疗的研究进展  

Research Progress in Interventional Therapy Combined with Targeted and Immunotherapy for Primary Liver Cancer

作　　者：甘心怡 杜文军[1] GAN Xinyi;DUWenjun(Shandong Public Health Clinical Center,Jinan,Shandong 250000,China)

机构地区：[1]山东大学附属公共卫生临床中心,山东济南250000

出　　处：《转化医学杂志》2024年第10期1802-1806,共5页Translational Medicine Journal

基　　金：山东自然科学基金资助项目(ZR2023MH143)。

摘　　要：肝细胞癌(HCC)发病率高,多数患者初次就诊时已经处于中晚期,此时不论是经血管介入治疗、靶向治疗还是免疫治疗,单一治疗手段疗效并不尽如人意。随着治疗技术的不断进步,介入联合靶向及免疫的三联治疗显示出较好的协同性。通过归纳总结国内外联合治疗现状,表明介入联合靶向及免疫治疗可以提高HCC患者生存率及疗效、延长患者生存期,并可有效提高初始不可切除HCC患者的手术切除率,给HCC的治疗带来了新思路。本文分析有关联合治疗的潜在机制,继而从临床应用、不良反应与疗效预测等方面简述主要进展,提出目前需要重视的研究难点与亟需解决的问题。Primary hepatocellular carcinoma(HCC)has a high incidence rate,and most patients are already in the mid-to-late stage at the time of initial diagnosis.For the treatment of such HCC patients,the efficacy of a single treatment modality,whether it is transvascular interventional therapy,targeted therapy or immunotherapy,is not entirely satisfactory.With the continuous advancement of treatment technology,the triple combination therapy of interventional therapy,targeted therapy and immunotherapy has demonstrated synergy.By summarizing the current status of combination therapy at home and abroad,it is shown that combination therapy can improve the survival rate and efficacy of patients,prolong the survival time of patients,and effectively increase the surgical resection rate of patients with initially unresectable HCC,bringing new ideas to the treatment of HCC.This article analyzes the potential mechanisms related to combination therapy,and then briefly describes the main progress in terms of clinical application,adverse reactions and efficacy prediction,and proposes the current research difficulties and problems that urgently need to be solved.

关 键 词：肝肿瘤 介入治疗 免疫治疗 分子靶向治疗 

分 类 号：R735.705[医药卫生—肿瘤]